Boston-Based AI Proteins Taps University of Missouri Expertise to Drive Advances in Cancer Therapeutics

• February 12, 2026

Key Takeaways: 

• AI Proteins has entered a collaborative research agreement with the University of Missouri to advance next-generation cancer therapeutics.
• The collaboration reinforces Missouri’s broader leadership in life sciences, biomanufacturing, and translational research.

Missouri’s life sciences ecosystem continues to gain national momentum, as AI Proteins enters into a collaborative research agreement with the University of Missouri to advance next-generation cancer therapies. The partnership underscores how academic excellence at Missouri’s flagship university is helping propel the state into a leadership role in life sciences innovation and biopharmaceutical development.

AI Proteins is a Boston-based biotechnology company that uses artificial intelligence and advanced laboratory technologies to design new protein-based medicines from scratch. Its decision to partner with the University of Missouri highlights not only the university’s growing reputation for cutting-edge biomedical research, but also Missouri’s emergence as a competitive destination for life sciences companies seeking research depth, specialized infrastructure, and translational expertise.

“AI Proteins recognizes Dr. Carolyn Anderson and her team as leaders in molecular imaging and theranostics research,” said Dr. Chris Bahl, Founder, President, and CEO of AI Proteins. “By working together, we have the opportunity to take a major step forward for patients who are battling cancer.”

According to TIME Magazine, the University of Missouri (Mizzou) ranks among the top universities in the world, reflecting its strong performance in research, academic excellence, and global impact. Mizzou ranks 13th among U.S. flagship universities,2nd among public SEC schools, and 124th out of 500 public and private universities worldwide, positioning it in the top quarter globally.

This academic strength feeds directly into Missouri’s broader life sciences and pharmaceutical manufacturing leadership. For the life sciences industry, Missouri offers a rare combination of:

• Federally funded research universities driving leading-edge life sciences discovery
• Specialized infrastructure supporting molecular imaging, nuclear science, and biomanufacturing
• Proven commercialization pathways that move innovation from lab to clinic
  

The AI Proteins–University of Missouri collaboration builds on this foundation. The research is expected to produce a scalable platform applicable across multiple cancer types, reinforcing both Mizzou’s role as a hub for high-impact medical innovation and Missouri’s growing influence in the national life sciences and biopharma landscape.